Page 1 | Search Results | Blood | American Society of Hematology

1-9 of 9

Sort by

Sort Order Select

Journal Articles

Evaluation of the Disease Risk Index on Outcomes Following Allogeneic Hematopoietic Cell Transplantation for Acute Myeloid Leukemia and Myelodysplastic Syndromes

Fotios V. Michelis, MDPhD, Hans A. Messner, MD PhD, Jieun Uhm, MD, Naheed Alam, MBBS,MD, David Loach, MD, Laura McGillis, NP, Anna Lambie, NP, Vikas Gupta, MD FRCP, FRCPath, John Kuruvilla, MD, Jeffrey H. Lipton, MD PhD, Matthew D. Seftel, MRCP, FRCPC, MPH, Dennis D. Kim, MD PhD

Blood (2014) 124 (21): 2529.

https://doi.org/10.1182/blood.V124.21.2529.2529

Published: 2014

Journal Articles

Development and Validation of a Prognostic Score Involving Disease Status, Patient Age and Donor Type for Outcomes of Allogeneic Hematopoietic Cell Transplantation in Patients with Acute Myeloid Leukemia

Fotios V. Michelis, MDPhD, Rouslan Kotchetkov, MD, Aamir Azeem, Rebecca M. Grunwald, Jieun Uhm, MD, Naheed Alam, MBBS, MD, Anna Lambie, NP, Laura McGillis, NP, David Loach, MD, Vikas Gupta, MD FRCP, FRCPath, John Kuruvilla, MD FRCPC, Jeffrey H. Lipton, MD PhD, Dennis D. Kim, MD PhD, Matthew D. Seftel, MRCP, FRCPC, MPH, Hans A. Messner, MD PhD

Blood (2014) 124 (21): 1237.

https://doi.org/10.1182/blood.V124.21.1237.1237

Published: 2014

Journal Articles

Incidence of Secondary Malignancies Following Allogeneic Hematopoietic Cell Transplantation: A Single Center Experience

Fotios V. Michelis, MDPhD, Rouslan Kotchetkov, MD, Rebecca M. Grunwald, Aamir Azeem, Jieun Uhm, MD, Naheed Alam, MBBS,MD, Laura McGillis, NP, Anna Lambie, NP, David Loach, MD, Vikas Gupta, MD FRCP, FRCPath, John Kuruvilla, MD FRCPC, Jeffrey H. Lipton, MD PhD, Dennis D. Kim, MD PhD, Matthew D. Seftel, MRCP, FRCPC, MPH, Hans A. Messner, MD PhD

Blood (2014) 124 (21): 1179.

https://doi.org/10.1182/blood.V124.21.1179.1179

Published: 2014

Journal Articles

Multiple CMV Reactivations Are Associated with Lower Risk of Relapse Following Reduced Intensity Conditioning Allogeneic Stem Cell Transplantation

Feras Alfraih, MD, Naheed Alam, MBBS,MD, Vikas Gupta, MD FRCP, FRCPath, Dennis Dong Hwan Kim, MDPhD, John Kuruvilla, MD, Jeffrey H. Lipton, MD PhD, David Loach, MD, Matthew D. Seftel, MRCP, FRCPC, MPH, Jieun Uhm, MD, Anna Lambie, NP, Hans A. Messner, PhD

Blood (2014) 124 (21): 3955.

https://doi.org/10.1182/blood.V124.21.3955.3955

Published: 2014

Journal Articles

A Risk Score to Predict CMV Viremia within the First 100 Days after Allogeneic Stem Cell Transplantation Based on Pre-Transplant Parameters

Feras Alfraih, MD, John Kuruvilla, MD, Naheed Alam, MBBS,MD, Anna Lambie, NP, Vikas Gupta, MD FRCP, FRCPath, Dennis Dong Hwan Kim, MDPhD, Matthew D. Seftel, MRCP, FRCPC, MPH, Jieun Uhm, MD, David Loach, MD, Eshetu G Atenafu, M.Sc., Jeffrey H. Lipton, MD PhD, Hans A. Messner, MD PhD

Blood (2014) 124 (21): 3877.

https://doi.org/10.1182/blood.V124.21.3877.3877

Published: 2014

Journal Articles

Clinical Characteristics, Risk Factors and Outcomes of CMV Disease after Allogeneic Stem Cell Transplantation

Feras Alfraih, MD, Naheed Alam, MBBS,MD, Anna Lambie, NP, Vikas Gupta, MD FRCP, FRCPath, Dennis Dong Hwan Kim, MDPhD, John Kuruvilla, MD, Jeffrey H. Lipton, MD PhD, Matthew D. Seftel, MRCP, FRCPC, MPH, Jieun Uhm, MD, David Loach, MD, Hans A. Messner, MD PhD

Blood (2014) 124 (21): 3879.

https://doi.org/10.1182/blood.V124.21.3879.3879

Published: 2014

Journal Articles

The Modified Pre-Transplant EBMT Risk Score Is Superior To The HCT-CI Score In Predicting Overall Survival and Non-Relapse Mortality After Allogeneic Hematopoietic Cell Transplantation In Patients With Acute Myeloid Leukemia

Fotios V. Michelis, MD, PhD, Hans A. Messner, MD, PhD, Jieun Uhm, MD, Anna Lambie, NP, Laura McGillis, NP, Vikas Gupta, MD, FRCP, FRCPath, John Kuruvilla, MD, FRCPC, Jeffrey H. Lipton, MD, PhD, Dennis Dong Hwan Kim, MD, PhD

Blood (2013) 122 (21): 2153.

https://doi.org/10.1182/blood.V122.21.2153.2153

Published: 2013

Journal Articles

A Comparison Of Long-Term Outcomes Of Donor Lymphocyte Infusions and Tyrosine Kinase Inhibitors In CML Patients Relapsed After Allogeneic Hemopoietic Stem Cell Transplantation

Mohamed Shanavas, MD, FRACP, FRCPA, Hans A. Messner, MD, PhD, Suzanne Kamel-Reid, PhD, Eshetu G Atenafu, MSc, Vikas Gupta, MD, FRCP, FRCPath, John Kuruvilla, MD, FRCPC, Dennis Dong Hwan Kim, MD, PhD, Jieun Uhm, MD, Anna Lambie, NP, Laura Ellis, NP, MN, RN (EC), Jeffrey H. Lipton, MD, PhD

Blood (2013) 122 (21): 5501.

https://doi.org/10.1182/blood.V122.21.5501.5501

Published: 2013

Journal Articles

CMV Reactivations and Their Impact On Outcomes in Patients After Hematopoietic Cell Transplantation

Naheed Alam, MBBS, Anna Lambie, NP, Yvette Neme Yunes, MD, Feras Alfraih, MD, Eshetu G Atenafu, MSc, Dennis Dong Hwan Kim, MD, PhD, Vikas Gupta, MD, FRCP, FRCPath, John Kuruvilla, MD, Jeff H Lipton, MD, Hans A. Messner, M.D./Ph.D

Blood (2012) 120 (21): 4501.

https://doi.org/10.1182/blood.V120.21.4501.4501

Published: 2012

NARROW

Evaluation of the Disease Risk Index on Outcomes Following Allogeneic Hematopoietic Cell Transplantation for Acute Myeloid Leukemia and Myelodysplastic Syndromes

Development and Validation of a Prognostic Score Involving Disease Status, Patient Age and Donor Type for Outcomes of Allogeneic Hematopoietic Cell Transplantation in Patients with Acute Myeloid Leukemia

Incidence of Secondary Malignancies Following Allogeneic Hematopoietic Cell Transplantation: A Single Center Experience

Multiple CMV Reactivations Are Associated with Lower Risk of Relapse Following Reduced Intensity Conditioning Allogeneic Stem Cell Transplantation

A Risk Score to Predict CMV Viremia within the First 100 Days after Allogeneic Stem Cell Transplantation Based on Pre-Transplant Parameters

Clinical Characteristics, Risk Factors and Outcomes of CMV Disease after Allogeneic Stem Cell Transplantation

The Modified Pre-Transplant EBMT Risk Score Is Superior To The HCT-CI Score In Predicting Overall Survival and Non-Relapse Mortality After Allogeneic Hematopoietic Cell Transplantation In Patients With Acute Myeloid Leukemia

A Comparison Of Long-Term Outcomes Of Donor Lymphocyte Infusions and Tyrosine Kinase Inhibitors In CML Patients Relapsed After Allogeneic Hemopoietic Stem Cell Transplantation

CMV Reactivations and Their Impact On Outcomes in Patients After Hematopoietic Cell Transplantation

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only